Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00038077 | Reversal of Ventricular Remodeling With Toprol-XL | PHASE3 | COMPLETED | 300 | — | — | Aug 1, 2001 | Sep 1, 2003 | Nov 19, 2010 | 44 | United States |
| Name | Type | Description |
|---|---|---|
| Seloken ZOK/Toprol-XL | DRUG | 50 mg |
| Placebo | DRUG | - |
Inclusion Criteria: * Diagnosis of stable asymptomatic heart failure. * Documented ejection fraction less than 0.40. * Must be able to comply with all study procedures. Exclusion Criteria: * Taken B-blocker therapy for longer than 1 week within 6 months prior to randomization. * Have heart proble...